CA2567937A1 - Arnmi viraux ou associes aux virus et leur utilisation - Google Patents

Arnmi viraux ou associes aux virus et leur utilisation Download PDF

Info

Publication number: CA2567937A1
Authority: CA; Canada
Prior art keywords: mirna; nucleic acid; sequence; expression; seq
Prior art date: 2004-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002567937A

Other languages

English (en)

Inventor

Itzhak Bentwich

Amir Avniel

Yael Karov

Ranit Aharonov

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Rosetta Genomics Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-26

Filing date

2005-05-26

Publication date

2005-12-08

2004-05-26 Priority claimed from US10/709,739 external-priority patent/US7777022B2/en

2005-05-26 Application filed by Individual filed Critical Individual

2005-12-08 Publication of CA2567937A1 publication Critical patent/CA2567937A1/fr

Status Abandoned legal-status Critical Current

Links

108091070501 miRNA Proteins 0.000 title claims abstract description 172
230000003612 virological effect Effects 0.000 title description 25
239000002679 microRNA Substances 0.000 claims abstract description 289
238000000034 method Methods 0.000 claims abstract description 39
239000000203 mixture Substances 0.000 claims abstract description 20
208000036142 Viral infection Diseases 0.000 claims abstract description 17
230000009385 viral infection Effects 0.000 claims abstract description 17
239000002243 precursor Substances 0.000 claims abstract description 13
150000007523 nucleic acids Chemical class 0.000 claims description 114
108020004707 nucleic acids Proteins 0.000 claims description 107
102000039446 nucleic acids Human genes 0.000 claims description 106
239000000523 sample Substances 0.000 claims description 106
108090000623 proteins and genes Proteins 0.000 claims description 102
230000014509 gene expression Effects 0.000 claims description 94
125000003729 nucleotide group Chemical group 0.000 claims description 65
239000002773 nucleotide Substances 0.000 claims description 62
238000009739 binding Methods 0.000 claims description 45
230000000295 complement effect Effects 0.000 claims description 39
238000000018 DNA microarray Methods 0.000 claims description 16
239000000758 substrate Substances 0.000 claims description 14
239000007787 solid Substances 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
239000012472 biological sample Substances 0.000 claims description 9
238000001727 in vivo Methods 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 8
238000000338 in vitro Methods 0.000 claims description 7
230000001575 pathological effect Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 2
238000003745 diagnosis Methods 0.000 abstract description 7
108091033319 polynucleotide Proteins 0.000 abstract description 5
102000040430 polynucleotide Human genes 0.000 abstract description 5
239000002157 polynucleotide Substances 0.000 abstract description 5
238000004393 prognosis Methods 0.000 abstract description 4
238000011282 treatment Methods 0.000 abstract description 3
108700011259 MicroRNAs Proteins 0.000 description 77
210000004027 cell Anatomy 0.000 description 63
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
201000010099 disease Diseases 0.000 description 46
210000001519 tissue Anatomy 0.000 description 43
108091007428 primary miRNA Proteins 0.000 description 23
238000009396 hybridization Methods 0.000 description 22
108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
108010058731 nopaline synthase Proteins 0.000 description 18
241000700605 Viruses Species 0.000 description 16
239000013598 vector Substances 0.000 description 16
241001465754 Metazoa Species 0.000 description 14
108020004999 messenger RNA Proteins 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 12
108700005078 Synthetic Genes Proteins 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 9
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 9
238000002493 microarray Methods 0.000 description 9
241000725303 Human immunodeficiency virus Species 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
230000007017 scission Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
238000003556 assay Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
230000003993 interaction Effects 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
238000010200 validation analysis Methods 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
241000196324 Embryophyta Species 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
238000000636 Northern blotting Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
238000010195 expression analysis Methods 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
125000000524 functional group Chemical group 0.000 description 5
239000000463 material Substances 0.000 description 5
-1 rRNA Proteins 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000012216 screening Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
108010090804 Streptavidin Proteins 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
238000004422 calculation algorithm Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229940000406 drug candidate Drugs 0.000 description 4
230000030279 gene silencing Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
239000006166 lysate Substances 0.000 description 4
108090000765 processed proteins & peptides Chemical group 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
125000002652 ribonucleotide group Chemical group 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
108700024394 Exon Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
108010057163 Ribonuclease III Proteins 0.000 description 3
108700005077 Viral Genes Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
238000001514 detection method Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
238000012226 gene silencing method Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
108020003589 5' Untranslated Regions Proteins 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000701489 Cauliflower mosaic virus Species 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
241000701832 Enterobacteria phage T3 Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
150000003838 adenosines Chemical class 0.000 description 2
238000003491 array Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000003100 immobilizing effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000035800 maturation Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108091023127 miR-196 stem-loop Proteins 0.000 description 2
239000003147 molecular marker Substances 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
230000001936 parietal effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
229920001184 polypeptide Chemical group 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000000754 repressing effect Effects 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
241000894007 species Species 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
210000003523 substantia nigra Anatomy 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
RLMLFADXHJLPSQ-NPPFTVEMSA-N (3s,6s,9s,12s,15s,18s,21s,24r,27s)-3,6-dibenzyl-12,24-bis[(2r)-butan-2-yl]-15-(2-hydroxypropan-2-yl)-4,10,16,22-tetramethyl-18-(2-methylpropyl)-9,21-di(propan-2-yl)-13-oxa-1,4,7,10,16,19,22,25-octazabicyclo[25.3.0]triacontane-2,5,8,11,14,17,20,23,26-nonon Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@H](C(=O)O[C@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1C)[C@H](C)CC)C(C)(C)O)=O)[C@H](C)CC)C1=CC=CC=C1 RLMLFADXHJLPSQ-NPPFTVEMSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
GZEFTKHSACGIBG-UGKPPGOTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-propyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(CCC)O[C@H](CO)[C@@H](O)[C@H]1O GZEFTKHSACGIBG-UGKPPGOTSA-N 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
240000000489 Agave utahensis Species 0.000 description 1
241000589155 Agrobacterium tumefaciens Species 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108700023863 Gene Components Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
241000560067 HIV-1 group M Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
101710149951 Protein Tat Proteins 0.000 description 1
238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000219870 Trifolium subterraneum Species 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000007244 Zea mays Nutrition 0.000 description 1
108010055615 Zein Proteins 0.000 description 1
108010084455 Zeocin Proteins 0.000 description 1
229920006397 acrylic thermoplastic Polymers 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
108010008887 aureobasidin A Proteins 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
XIOUCIKZATWNIJ-UHFFFAOYSA-N azii Chemical compound O1C(C)=C(O)C(=O)CC1OC1C2(C)CCC3(C)C4(C)CCC5C(C)(CO)C(OC6C(C(O)C(O)C(O6)C(O)=O)OC6C(C(O)C(O)C(O6)C(O)=O)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC=C3C2CC(C)(C)C1 XIOUCIKZATWNIJ-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000002079 cooperative effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
101150027734 cript gene Proteins 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000037440 gene silencing effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000001905 globus pallidus Anatomy 0.000 description 1
210000004326 gyrus cinguli Anatomy 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
108091007426 microRNA precursor Proteins 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
238000000206 photolithography Methods 0.000 description 1
230000009894 physiological stress Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920001748 polybutylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008672 reprogramming Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003290 ribose derivatives Chemical group 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002924 silencing RNA Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
150000003376 silicon Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009752 translational inhibition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Virology (AREA)
Microbiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Analytical Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

CA002567937A 2004-05-26 2005-05-26 Arnmi viraux ou associes aux virus et leur utilisation Abandoned CA2567937A1 (fr)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US10/709,739 US7777022B2 (en)	2002-12-05	2004-05-26	Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
US10/709,739		2004-05-26
US52245004P	2004-10-03	2004-10-03
US52245104P	2004-10-03	2004-10-03
US60/522,451		2004-10-03
US60/522,450		2004-10-03
US52245904P	2004-10-04	2004-10-04
US60/522,459		2004-10-04
US66509405P	2005-03-25	2005-03-25
US60/665,094		2005-03-25
PCT/IB2005/002352 WO2005116250A2 (fr)	2004-05-26	2005-05-26	Arnmi viraux ou associes aux virus et leur utilisation

Publications (1)

Publication Number	Publication Date
CA2567937A1 true CA2567937A1 (fr)	2005-12-08

Family

ID=42331989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002567937A Abandoned CA2567937A1 (fr)	2004-05-26	2005-05-26	Arnmi viraux ou associes aux virus et leur utilisation

Country Status (7)

Country	Link
EP (1)	EP1751311A2 (fr)
JP (1)	JP2008500039A (fr)
CN (1)	CN101031658A (fr)
AU (1)	AU2005248149A1 (fr)
CA (1)	CA2567937A1 (fr)
IL (1)	IL179545A (fr)
WO (1)	WO2005116250A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040219565A1 (en)	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US20090123912A1 (en) *	2005-01-25	2009-05-14	Rosetta Inpharmatics Llc	Methods for quantitating small RNA molecules
US8071306B2 (en)	2005-01-25	2011-12-06	Merck Sharp & Dohme Corp.	Methods for quantitating small RNA molecules
CA2610702A1 (fr) *	2005-06-03	2006-12-07	Michael Zenon Michael	Ciblage de cellules presentant un microarn d'expression modifiee
HUE031322T2 (hu) *	2006-03-31	2017-07-28	Mobidiag Oy	Eljárás és mikrotömb herpesz vírusok kimutatására
US8007790B2 (en)	2006-04-03	2011-08-30	Stowers Institute For Medical Research	Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7727725B2 (en)	2006-04-27	2010-06-01	Celera Corporation	Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
EP2038432B1 (fr) *	2006-06-30	2017-02-08	Rosetta Genomics Ltd	Procede pour detecter et quantifier des acides nucleiques cibles generes par rt-pcr de miarn
EP2104742B1 (fr) *	2006-11-21	2014-05-07	Jawaharlal Nehru Centre for Advanced Scientific Research	Essai de sensibilité élevée pour le typage moléculaire d'un échantillon biologique, sondes et un coffret de celles-ci
SG143090A1 (en) *	2006-11-27	2008-06-27	Agency Science Tech & Res	Influenza b virus detection method and kit therefor
US8481506B2 (en)	2006-12-05	2013-07-09	Rosetta Genomics, Ltd.	Nucleic acids involved in viral infection
EP2641976A3 (fr) *	2009-01-16	2014-01-08	Cepheid	Méthodes de détection du cancer du col de l'utérus
US20100240049A1 (en)	2009-01-16	2010-09-23	Cepheid	Methods of Detecting Cervical Cancer
AU2011205230A1 (en)	2010-01-13	2012-08-02	Caris Life Sciences Switzerland Holdings Gmbh	Detection of gastrointestinal disorders
CA2787385C (fr) *	2010-01-18	2018-12-11	Universiteit Utrecht Holding B.V.	Moyens et procedes pour distinguer fecv et fipv
CN103237901B (zh)	2010-03-01	2016-08-03	卡里斯生命科学瑞士控股有限责任公司	用于治疗诊断的生物标志物
KR20130043104A (ko)	2010-04-06	2013-04-29	카리스 라이프 사이언스 룩셈부르크 홀딩스	질병용 순환 생물학적 지표들
RU2624048C2 (ru)	2010-10-06	2017-06-30	Курна, Инк.	Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
WO2013040429A1 (fr)	2011-09-14	2013-03-21	Rana Therapeutics Inc.	Composés oligonucléotidiques multimères
US20130302784A1 (en) *	2012-03-30	2013-11-14	Intelligent Medical Devices, Inc.	Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of herpes simplex virus
AU2013205110B2 (en)	2012-04-24	2016-10-13	Gen-Probe Incorporated	Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
US11033620B2 (en)	2014-06-09	2021-06-15	Biomed Valley Discoveries, Inc.	Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191568A2 (fr)	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Polythérapies utilisant des agents qui ciblent des stromas associés à une tumeur ou des cellules tumorales et la vasculature tumorale
WO2015191596A1 (fr)	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Polythérapies utilisant des agents de platine et des agent ciblant le stroma associé à une tumeur ou des cellules tumorales
WO2015191610A2 (fr)	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Polythérapies utilisant des agents qui ciblent un stroma associé à une tumeur ou des cellules tumorales et d'autres voies
US10758613B2 (en)	2014-06-09	2020-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health	Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191583A2 (fr)	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Polythérapie ciblant des stromas ou des cellules tumorales et des topoisomérases
US10556020B2 (en)	2014-09-26	2020-02-11	University Of Massachusetts	RNA-modulating agents
US10758558B2 (en)	2015-02-13	2020-09-01	Translate Bio Ma, Inc.	Hybrid oligonucleotides and uses thereof
WO2017004079A1 (fr)	2015-06-29	2017-01-05	Biomed Valley Discoveries, Inc.	Combinaison d'inhibiteurs de lpt-723 et de point de contrôle immunitaire et méthodes de traitement
WO2017134529A1 (fr) *	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Substances et méthodes pour le traitement d'une immunodéficience combinée sévère (idcs) ou syndrome d'omenn
KR20190017872A (ko)	2016-06-08	2019-02-20	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	염증 및 면역 반응 유도를 감소시키는 조작된 바이러스 벡터
SG11201810670VA (en) *	2016-06-14	2018-12-28	Agency Science Tech & Res	Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma
WO2019028055A1 (fr)	2017-07-31	2019-02-07	The Trustees Of Columbia Univeristy In The City Of New York	Composés, compositions et procédés de traitement de la leucémie lymphoblastique aiguë à lymphocytes t
EP3707262A1 (fr)	2017-11-08	2020-09-16	President and Fellows of Harvard College	Compositions et procédés d'inhibition de réponses inflammatoires induites par un vecteur viral
WO2019204864A1 (fr) *	2018-04-23	2019-10-31	Simpori Pty Ltd	Désinfectant microbien à large application
JP7473113B2 (ja) *	2018-07-31	2024-04-23	国立大学法人大阪大学	オリゴヌクレオチドを含有する小細胞肺癌治療薬
US20210332367A1 (en) *	2018-09-18	2021-10-28	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20230150844A (ko)	2021-02-26	2023-10-31	알닐람 파마슈티칼스 인코포레이티드	케토헥소키나아제(KHK) iRNA 조성물 및 이의 사용 방법
CA3213775A1 (fr)	2021-04-19	2022-10-27	Utsav SAXENA	Compositions et procedes pour inhiber l'expression de l'element 3 du groupe h de la sous-famille 1 de recepteur nucleaire (nr1h3)
WO2023031418A1 (fr) *	2021-09-03	2023-03-09	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Aptamères d'adn et leur utilisation dans le (pré)diagnostic du cancer
US11898186B1 (en)	2022-08-10	2024-02-13	Genscript Usa Inc.	Compositions and methods for preparing capped mRNA

2005
- 2005-05-26 CA CA002567937A patent/CA2567937A1/fr not_active Abandoned
- 2005-05-26 EP EP05774516A patent/EP1751311A2/fr not_active Withdrawn
- 2005-05-26 JP JP2007514216A patent/JP2008500039A/ja not_active Withdrawn
- 2005-05-26 AU AU2005248149A patent/AU2005248149A1/en not_active Abandoned
- 2005-05-26 WO PCT/IB2005/002352 patent/WO2005116250A2/fr active Application Filing
- 2005-05-26 CN CNA2005800253004A patent/CN101031658A/zh active Pending
2006
- 2006-11-23 IL IL179545A patent/IL179545A/en unknown

Also Published As

Publication number	Publication date
WO2005116250A3 (fr)	2006-07-06
AU2005248149A1 (en)	2005-12-08
EP1751311A2 (fr)	2007-02-14
IL179545A0 (en)	2007-05-15
IL179545A (en)	2010-12-30
WO2005116250A2 (fr)	2005-12-08
WO2005116250A8 (fr)	2007-07-05
JP2008500039A (ja)	2008-01-10
CN101031658A (zh)	2007-09-05

Publication	Publication Date	Title
US9624556B2 (en)	2017-04-18	Viral and viral associated miRNAs and uses thereof
CA2567937A1 (fr)	2005-12-08	Arnmi viraux ou associes aux virus et leur utilisation
AU2005243410B2 (en)	2010-04-22	Micronas and uses thereof
US7642348B2 (en)	2010-01-05	Prostate cancer-related nucleic acids
US7592441B2 (en)	2009-09-22	Liver cancer-related nucleic acids
US20080182237A1 (en)	2008-07-31	Lung cancer-related nucleic acids
WO2009024834A2 (fr)	2009-02-26	Acides nucléiques impliques dans les infections virales
US20110189766A1 (en)	2011-08-04	Micrornas and uses thereof
US20070166724A1 (en)	2007-07-19	Micrornas and related nucleic acids
US20070259349A1 (en)	2007-11-08	Bladder cancer-related nucleic acids

Legal Events

Date	Code	Title	Description
2008-05-05	EEER	Examination request
2011-05-26	FZDE	Discontinued